The effects of CBD on cell viability werenot blocked by cannabinoid receptor antagonists, a transient receptorpotential vanilloid 1 (TRPV1) channel blocker, or an agonist of theG-protein-coupled receptor GPR55, suggesting that CBD acts independentlyof these targets in prostate cancer cells. Here, TRPV1 is linked to prostate carcinoma.